Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The OX-TES-4 antigen originally elicited an antibody response in 50% of diffuse large B-cell lymphoma (DLBCL) patients but not in control subjects. OX-TES-4 is encoded by a novel gene, MORC4, located at chromosome Xq22.3. The MORC4 protein contains a HATPase-c domain, CW zinc finger motif, nuclear localisation signals and a nuclear matrix-binding domain, together with a coiled-coil region. MORC4 mRNA is widely expressed at low levels in normal tissues, showing highest expression levels in placenta and testis. mRNA levels were increased in non-germinal centre-derived DLBCL and Hodgkin lymphoma cell lines, compared with germinal centre-derived DLBCL cell lines and normal B cells. Nineteen DLBCL patients (66%) expressed significantly higher levels of MORC4 mRNA than normal B cells (P = 0.0031). The differential expression of MORC4 identifies this molecule as a potential lymphoma biomarker, whose overexpression may contribute to the immunological recognition of MORC4 by a subgroup of DLBCL patients.

Original publication

DOI

10.1111/j.1365-2141.2007.06680.x

Type

Journal article

Journal

Br J Haematol

Publication Date

08/2007

Volume

138

Pages

479 - 486

Keywords

B-Lymphocytes, Base Sequence, Biomarkers, Tumor, Cell Line, Tumor, Female, Gene Expression Profiling, Humans, In Situ Hybridization, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Male, Molecular Sequence Data, Nuclear Proteins, Oligonucleotide Array Sequence Analysis, Placenta, Pregnancy, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Sequence Alignment, Testis